Abstract
Introduction Many recent researches have contributed immensely in the management of retinal diseases. In this critical review, we discuss the management of retinal diseases. Conclusion Currently, age-related macular degeneration is managed primarily by anti-vascular growth factor agents. Newer reports on combination therapy may help in managing this visually debilitating condition in a better way. There are many new reports regarding the use of aflibercept and Ozurdex® (Allergan Inc., Irvine, California, USA) in the management of diabetic macular oedema and macular oedema associated with retinal vein occlusions. In the light of recent reports, retinopathy of prematurity may be often managed with bevacizumab. Introduction of ocriplasmin and Argus-II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, California, USA) may offer ophthalmologists newer ways to treat some important vitreoretinal conditions.
Highlights
Many recent researches have contributed immensely in the management of retinal diseases
It is important to critically review important ones to adopt them into our clinical practice
In cases of juxtafoveal Choroidal neovascular membrane (CNVM), the loss was 49% in treated eyes and 68% in untreated eyes at three years. This landmark study, for the first time, showed that some stabilisation of visual acuity could be achieved in selected types of CNVM
Summary
Retinal diseases constitute a significant part of the visually disabling ocular disease spectrum. There have been many exciting developments in the understanding, diagnosis and management of retinal diseases. It is important to critically review important ones to adopt them into our clinical practice. In this critical review, we shall discuss conditions like age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), vitreomacular traction syndrome and retinopathy of prematurity (ROP), in addition to vitreoretinal surgery
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call